PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|January 3, 2019
Rentschler Biopharma Completes Acquisition of US Manufacturing Site
Author(s)Pharmaceutical Technology Editors
The Massachusetts site, formerly associated with an affiliate of Shire, is Rentschler Biopharma’s first facility in the US.
Advertisement
Rentschler Biopharma, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, completed the acquisition of a manufacturing facility from an affiliate of Shire, the company announced in a January 3, 2019 press release. The 93,000-ft2 site with approximately 70 employees is located near Boston in Milford, MA, and it is the German company’s first manufacturing facility in the United States. Under the terms of the agreement, Rentschler Biopharma will continue to manufacture for Shire at the site.
“The acquisition of this modern facility fits perfectly with our strategy to further strengthen and secure our world-class CDMO position in a growing and changing market. The US is a key market for Rentschler Biopharma, and this site gives us a firm foothold in this important area of growth, enabling us to better meet our clients’ needs,” said Frank Mathias, CEO of Rentschler Biopharma, in the press release.
Dr. Ralf Otto, COO of Rentschler Biopharma, added: “We will continue to make investments in our business to ensure we have the advanced technologies to remain an innovation leader in the field and the capacity to remain competitive and grow with our clients. This includes future plans to qualify the Milford site as a multi-product manufacturing facility.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement